RESUMO
Travel for transplantation and transplant commercialism have become major issues in the last years, generating a passionate medical, legal, and ethical debate. We evaluated the general characteristics of patients who received a kidney transplant abroad and were subsequently followed in our institution. Then, we carried out a retrospective analysis of travelers' outcomes and compared them with a matched cohort of patients transplanted in our center. Between 1971 and 2008, 58 kidney transplants were performed outside Argentina and were subsequently followed up at our institution. The main destinations were the USA (32.8%), Bolivia (29.3%), and Brazil (17.2%). Deceased donor transplants were the most common (53.4%) followed by unrelated living donors (32.8%). No difference was observed between travelers and controls in terms of one-month and one-yr renal function and one-yr and five-yr graft survival. Travelers had significantly less time on dialysis before transplantation than controls. The major destination among all travelers was the USA, and the main destination for commercial transplants was Bolivia. The destination countries involved in our study and the apparent non-inferiority of travelers graft outcomes differ from those of previous reports.
Assuntos
Rejeição de Enxerto/mortalidade , Sobrevivência de Enxerto , Transplante de Rim/mortalidade , Complicações Pós-Operatórias/mortalidade , Obtenção de Tecidos e Órgãos/métodos , Viagem , Adulto , Argentina , Estudos de Casos e Controles , Feminino , Seguimentos , Hospitais Universitários , Humanos , Falência Renal Crônica/cirurgia , Masculino , Pessoa de Meia-Idade , Prognóstico , Sistema de Registros , Estudos Retrospectivos , Taxa de Sobrevida , Fatores de Tempo , Doadores de TecidosRESUMO
The tumor lysis syndrome (TLS) is a metabolic disorder resulting from a massive tumor breakdown. It is characterized by hyperuricemia, hyperphosphatemia, hypocalcemia and hyperkalemia and predisposes to acute renal failure. TLS usually occurs after the initiation of cytotoxic therapy and is more frequent in the case of neoplasias with a high proliferative rate or that are highly chemo-sensitive. We report the case of a man with a recurrent kidney cancer who presented with a TLS and acute renal failure after initiation of sunitinib.
Assuntos
Inibidores da Angiogênese/efeitos adversos , Carcinoma de Células Renais/tratamento farmacológico , Indóis/efeitos adversos , Neoplasias Renais/tratamento farmacológico , Pirróis/efeitos adversos , Síndrome de Lise Tumoral/etiologia , Evolução Fatal , Humanos , Masculino , Pessoa de Meia-Idade , SunitinibeRESUMO
El síndrome de lisis tumoral (SLT) es un trastorno metabólico que ocurre como consecuencia de una destrucción celular masiva. Se caracteriza por la presencia de hiperuricemia, hiperfosfatemia, hipocalcemia e hiperkalemia, y predispone al desarrollo de insuficiencia renal aguda. En la mayoría de los casos el SLT ocurre luego de instaurarse un tratamiento antitumoral y es más frecuente en tumores de alto grado de malignidad y alta sensibilidad a la quimioterapia. Presentamos el caso de un paciente con diagnóstico de cáncer de riñón recidivado que presenta un SLT e insuficiencia renal aguda luego de iniciar tratamiento con sunitinib.
The tumor mor lysis syndrome (TLS) is a metabolic disorder resulting from a massive tumor breakdown. It is characterized by hyperuricemia, hyperphosphatemia, hypocalcemia and hyperkalemia and predisposes to acute renal failure. TLS usually occurs after the initiation of cytotoxic therapy and is more frequent in the case of neoplasias with a high proliferative rate or that are highly chemo-sensitive. We report the case of a man with a recurrent kidney cancer who presented with a TLS and acute renal failure after initiation of sunitinib.